O papel do polimorfismo genético do EGF+61 A/G no risco de desenvolvimento e progressão do adenocarcinoma colorretal

Abstract

Introduction: Colon cancer is quite common in men and women worldwide, in Brazil and specifically in São Paulo, some genetic polymorphisms (SNPs) may be associated with the development of neoplasms of epithelial origin, such as colon polymorphism epidermal growth factor (EGF+61 A/G) Objective: analyze the role of genetic polymorphisms of EGF+61 in the risk and prognosis of colon adenocarcinoma, the role of this polymorphic variant in the susceptibility of developing colon and rectum adenocarcinoma Materials and methods: cross-sectional case-control study analysis was performed using Python programming language and machine learning algorithms to perform statistical modeling. Results: 187 individuals participated in the study, of which 112 were in the case group and 72 in the control group, 48.21% male and 50.89% female. The mean age of the case group was 58 years and the control group 59 years. Of the patients in the case group, 6% (7 patients) present with clinical stage I, 31% (35 patients) with clinical stage II, 38% (43 patients) with clinical stage III and 23% (26 patients) with clinical stage IV. It is possible to observe that probabilistically 27 out of 47 of the participants without cancer with the A/G polymorphism may not have the oncological condition and 20 out of 47 may develop the condition, that is 57.45% and 42.55%, respectively, of patients with cancer and polymorphism, 55.56% will not have disease progression and 44.44% may have progression. Conclusion: Our study revealed a correlation of patients with the EGF +61 A/G polymorphism with a 42% possibility of developing colorectal cancer throughout life. Patients with the polymorphism and also with neoplasia have a 44% chance of disease progression.